uniQure NV (QURE) (Q3 2026) Earnings Call Highlights: FDA Priority Review for AMT-130 and a ... - Yahoo Finance
Yahoo Finance · Nov 4, 9:11 PM
Earnings call transcript: uniQure posts Q3 2026 EPS beat as FDA review advances - Investing.com
Investing.com · Nov 4, 2:42 PM
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update - GlobeNewswire
GlobeNewswire · Nov 4, 12:05 PM
Market reactionShares fell 10% on Nov 5.
uniQure is a gene therapy company; its hemophilia B therapy HEMGENIX is sold by CSL Behring, and it has filed AMT-130, a one-time brain-injected treatment for Huntington's disease, for FDA approval.
uniQure submitted a BLA for AMT-130 in Huntington's disease on September 2, 2026, seeking accelerated approval on three-year data compared with an external natural-history control. FDA's July minutes called this approach reasonable but want a confirmatory study agreed and well underway. The four-year analysis, released September 29, showed 44% slowing on cUHDRS (nominal p=0.144) against an updated control, weaker than the 75% at three years. Cash of $810.3 million funds operations into 2030.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: FDA accepts the AMT-130 BLA for review
Does FDA accept the AMT-130 BLA for review, and with priority review?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
AMT-130 BLA filed on three-year data; four-year analysis missed significance on cUHDRS
BLA filed for Huntington's gene therapy on an externally controlled 36-month efficacy analysis; FDA's willingness to approve that evidence package is the only question that matters
First gene therapy BLA for Huntington's disease rides on FDA accepting single-arm, external-control Phase I/II data as registrational evidence
AMT-130 BLA submission for Huntington's disease tests whether FDA's accelerated approval reversal translates into a first-in-class gene therapy approval
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neurology and pain, Blood disorders, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
6 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.